{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-040641","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.503401+00:00","generated_at":"2026-05-23T03:58:21.098925+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiniksa Q1 2025 ARCALYST revenue $137.8M (+75% YoY); guides FY 2025 to $590-605M","bullets":["ARCALYST net product revenue $137.8M in Q1 2025, up 75% YoY; net income $8.5M vs loss of $17.7M in Q1 2024.","Full-year 2025 ARCALYST net product revenue guidance raised to $590-605M from prior $560-580M.","KPL-387 Phase 2/3 trial in recurrent pericarditis on track to initiate mid-2025; Phase 2 data expected 2H 2026.","Cash and investments $268.3M, no debt; current operating plan expected cash flow positive annually.","Tariff impact on ARCALYST gross margin expected immaterial; manufacturing transfer to Samsung Biologics ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-040641","json":"https://secwatch.observer/filing/0001104659-25-040641.json","markdown":"https://secwatch.observer/filing/0001104659-25-040641.md","text":"https://secwatch.observer/filing/0001104659-25-040641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925040641/0001104659-25-040641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925040641/tm2513395d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T03:58:21.098925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}